NCT03470805 - Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 21, 2018

Primary Completion Date

July 27, 2022

Study Completion Date

July 27, 2022

Conditions

Ovarian Cancer

Interventions

DRUG

Olaparib

Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until disease progression, unacceptable toxicity, withdraws from the study or closure of the study

Trial Locations (16)

14004

H Reina Sofía Cordoba, Córdoba

28046

Hospital Universitario La Paz, Madrid

39008

Hospital Universitario de Valdecilla, Santander

46009

Instituto Valenciano de Oncología, Valencia

Unknown

ICO Badalona, Badalona

Hospital de Guadalajara, Guadalajara

Complejo Hospitalario de Jaen, Jaén

Hospital de Jerez de la Frontera, Jerez de la Frontera

Hospital Lucus Augusti, Lugo

Fundación Jimenez Diaz, Madrid

Hospital Ramon y Cajal, Madrid

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario Puerta de Hierro, Madrid

Hospital Clinico Universitario Virgen Arrixaca, Murcia

Hospital Universitario Virgen del Rocío, Seville

Hospital Virgen Macarena, Seville